Skip to main content
EJNMMI Research
Fig. 4 | EJNMMI Research

Fig. 4

From: 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy

Fig. 4

a Western blot analysis of lysates from endpoint CWR22Res and 22Rv1 orthografts in castrated mice. Each lane contains lysate from an individual tumour. HSC70 used as loading control. (Molecular weights: SLC3A2, 80–85 kDa; SLC7A, kDa, 39 kDa; SLC1A5, 56 kDa; HSC70 70 kDa) (Left and right panels were each performed on a single blot respectively). b Quantitative RT-PCR analysis of SLC1A5 and SLC7A5 mRNA expression in orthografts. Hormone-naïve CWR22Res tumours obtained from uncastrated (androgen-proficient) mice were included as controls. CWR22Res and 22Rv1 tumours from experimental castrated mice mimic clinical tumours following acute and chronic ADT (n = 4 for CWR22Res, n = 3 for 22Rv1). Each data point is data from an individual tumour, with six technical repeats for each sample. c Heatmap showing mRNA expression levels (z scores) of significantly (p-adj < 0.05) differentially expressed amino acid transporters. Each sample analysed was from an individual tumour from endpoint mice bearing CWR22Res and 22Rv1 orthografts

Back to article page